biosensors

Biolinq's new funding was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. 

ReMix, a new technology in the works at MIT's Computer Science and Artificial Intelligence Laboratory, seeks to make progress toward a new paradigm of treatment – one that's less reliant on endoscopy and surgery, but instead relies on sensors and what scientists call an "in-body GPS" to help make diagnoses and guide drug administration.

Profusa, a company that is developing connected tissue-implanted biosensors, has raised just over $45 million in Series C funding.

When monitoring heart rate, skin temperatures, activity and other physiological data, biometric-sensing wearables are also tracking important indications of abnormality associated with infection, inflammation or even insulin.